OKYO Pharma Limited
OKYO · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.03 | -0.04 | -0.80 |
| FCF Yield | -3.61% | -22.00% | -20.60% | -10.03% |
| EV / EBITDA | -6.86 | -2.69 | -2.70 | -8.34 |
| Quality | ||||
| ROIC | 76.49% | 267.29% | -8,077.42% | -184.65% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.23 | 0.56 | 0.58 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 80.91% | -23.24% | -40.80% | -240.34% |
| Safety | ||||
| Net Debt / EBITDA | 0.22 | 0.05 | 0.14 | 0.43 |
| Interest Coverage | -8.14 | -14.90 | -135.36 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.02 | -1.63 |
| Cash Conversion Cycle | -1,125,046.78 | -578,574.28 | -82,043.19 | -78,205.81 |